Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis, Inc. (Nasdaq: PSNL) reported Q4 2021 revenue of $20.7 million, a 3% increase from Q4 2020. Revenue from biopharma customers, excluding the VA MVP, surged 102% to $15.4 million. However, revenue from the VA MVP fell 58% to $5.3 million. For the full year, revenue reached $85.5 million, a 9% increase. Operating expenses were $28.2 million in Q4, leading to a net loss of $20.2 million. The company forecasts $67.0 million in revenue for 2022, with a net loss between $110.0 million and $115.0 million.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced that its management will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 p.m. Eastern Time. The company specializes in providing precision cancer therapies and diagnostics through its Personalis NeXT Platform, offering insights into all human genes and the immune system from a single sample. The clinical laboratory is highly accredited, emphasizing quality and efficiency.
Personalis, Inc. (NASDAQ: PSNL) announced a strategic partnership with the Moores Cancer Center at UC San Diego Health to enhance clinical diagnostic testing for patients with advanced tumors. This collaboration aims to utilize Personalis' advanced genomic tumor profiling test to inform FDA-approved therapy decisions and clinical trial options. The partnership also focuses on developing novel biomarkers and conducting research on a liquid biopsy assay that significantly improves sensitivity for detecting minimal residual disease and cancer recurrence, enhancing patient care.
Personalis, Inc. (NASDAQ: PSNL) announced that it will release its fourth quarter and full-year 2021 financial results on February 24, 2022. A conference call and webcast will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and recent highlights. Interested parties can access the call via telephone or through the company's website. Personalis specializes in advanced cancer genomics, offering the Personalis NeXT Platform, which provides insights into approximately 20,000 human genes.
Personalis, Inc. (NASDAQ: PSNL), a leader in advanced cancer genomics, announced its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 2:00 p.m. Eastern Time. The event will be accessible via a webcast link for attendees. Personalis is known for its Personalis NeXT Platform®, which provides comprehensive genomic information from tissue samples, facilitating precision cancer therapies and diagnostics. The lab is CLIA certified and CAP accredited, ensuring clinical accuracy and efficiency.
Personalis, Inc. (PSNL) announced preliminary revenue estimates for Q4 and the full year of 2021, reporting approximately $20.7 million for Q4 and $85.5 million for the full year. Revenue from biopharma customers reached $15.4 million in Q4 2021, reflecting a 102% increase year-over-year. However, revenue from the U.S. Department of Veterans Affairs Million Veterans Program fell 58% to $5.3 million in Q4 and decreased 19% for the year. The company holds an estimated $287 million in cash as of December 31, 2021.
Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, will present at the 24th Annual Needham Virtual Growth Conference on January 11, 2022. The company's innovative Personalis NeXT Platform® provides comprehensive genomic insights from tissue samples, aiding in precision oncology. Furthermore, Personalis is a key provider for Veterans Affairs' Million Veteran Program, reinforcing its position in population sequencing. The firm's lab emphasizes clinical accuracy with necessary certifications, ensuring top-tier service in advanced cancer diagnostics.
Personalis, Inc. (NASDAQ: PSNL) announced the launch of NeXT Personal, a next-generation tumor-informed liquid biopsy assay that enhances detection of molecular residual disease (MRD) with a sensitivity down to 1 part-per-million. This marks a 10- to 100-fold improvement over existing technologies, enabling earlier detection across various cancers, including challenging low mutational burden and early-stage cancers. NeXT Personal creates a tailored liquid biopsy panel from a patient’s tumor to better monitor cancer treatment.
Personalis, Inc. (NASDAQ: PSNL) announced participation in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021. This event showcases Personalis' leadership in advanced cancer genomics aimed at precision cancer therapies. Interested parties can access a pre-recorded webcast of the presentation for 90 days through their website. Personalis’ NeXT Platform® supports comprehensive genomic insights from tissue samples, enhancing diagnostics for biopharmaceutical customers. For further details, visit investors.personalis.com.
Summary not available.